Eric Shroff Sells 709 Shares of Abbott Laboratories (NYSE:ABT) Stock

Abbott Laboratories (NYSE:ABT) SVP Eric Shroff sold 709 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the sale, the senior vice president directly owned 39,164 shares of the company’s stock, valued at approximately $4,526,575.12. This trade represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $113.09 on Thursday. The firm’s 50 day moving average price is $116.67 and its two-hundred day moving average price is $124.91. The stock has a market cap of $196.51 billion, a PE ratio of 30.40, a PEG ratio of 1.81 and a beta of 0.74. Abbott Laboratories has a 52-week low of $105.27 and a 52-week high of $139.15. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter in the prior year, the business posted $1.34 EPS. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s payout ratio is presently 67.74%.

Institutional Trading of Abbott Laboratories

Institutional investors have recently modified their holdings of the company. Brighton Jones LLC boosted its position in Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after acquiring an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC boosted its holdings in Abbott Laboratories by 3.5% during the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after purchasing an additional 162 shares during the last quarter. United Bank grew its position in Abbott Laboratories by 7.4% in the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after purchasing an additional 2,001 shares in the last quarter. GHP Investment Advisors Inc. increased its stake in Abbott Laboratories by 0.8% in the 2nd quarter. GHP Investment Advisors Inc. now owns 29,713 shares of the healthcare product maker’s stock valued at $4,041,000 after buying an additional 222 shares during the last quarter. Finally, Versor Investments LP bought a new stake in Abbott Laboratories during the 2nd quarter worth about $408,000. 75.18% of the stock is currently owned by institutional investors.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: FDA approved Abbott’s redesigned CardioMEMS Hero remote heart‑failure monitor — a smaller, lighter reader that could improve clinician workflows and patient adoption, supporting long‑term device revenue growth. How FDA Approval of CardioMEMS Hero Remote Monitor At Abbott (ABT) Has Changed Its Investment Story
• Neutral Sentiment: Several insiders (senior VPs/EVPs) disclosed small sales of ABT shares on Mar. 2 — amounts are modest relative to their remaining holdings and likely represent routine portfolio management rather than a clear signal. Abbott Laboratories Insider Selling
• Neutral Sentiment: Elevated investor attention — Zacks flags ABT as drawing interest, which can amplify moves in either direction but doesn’t by itself change fundamentals. Abbott Laboratories (ABT) is Attracting Investor Attention
• Negative Sentiment: Revenue miss in the latest quarter (reported $11.46B vs. consensus ≈ $11.8B) — EPS met estimates but the top‑line shortfall and softer near‑term trends have left analysts cautious and pressured the stock. Abbott (ABT) Stock Sinks As Market Gains: Here’s Why
• Negative Sentiment: Legal risk: Abbott is set to face trial over claims that a premature‑infant formula caused a deadly disease — a high‑visibility lawsuit that could create financial and reputational downside depending on outcomes or settlements. Abbott set to face trial over claims premature infant formula caused deadly disease

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ABT. Barclays decreased their price objective on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a report on Monday, February 2nd. Raymond James Financial decreased their price target on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Leerink Partners dropped their price objective on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a research note on Friday, January 30th. Freedom Capital upgraded Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Finally, Royal Bank Of Canada lowered their price target on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $137.05.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.